Partnering opportunities

Adjuvantix are currently seeking parties interested in entering into co-development alliances for its ADX40-TB and ADX40-Lymphoma candidate products.

In addition Adjuvantix has a body of preclinical data on the use of ADX40 with viral vaccines, including influenza and HSV and would welcome expressions of interest to partner or acquire product development rights in these areas.

To discuss partnering opportunities please contact Paul Jenkins at pauljenkins2@ntlworld.com and on +44 (0) 7702 871 433

Partnering